B+
Bull case
25%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-07-04 · RankAlpha Sentiment Codex
JSPR
Jasper TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The primary-source record supports constructive clinical positioning for briquilimab in CSU, with management highlighting positive January data, dose selection progress, and protocol refiling ahead of a planned Phase 2b study [#SEC-8K-2026-05-14].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
As a low-coverage micro-cap biotech, Jasper faces elevated volatility and thin external validation if milestones slip or financing terms are punitive.
Momentum
61
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.45 · Bull $0.90 · Bear $0.20Analysis 2026-07-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum61 · Δ7d -
Value41 · Δ7d -0.0
Sentiment31 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • As a low-coverage micro-cap biotech, Jasper faces elevated volatility and thin external validation if milestones slip or financing terms are punitive.
- • Clinical execution risk remains meaningful despite improved data, especially around successful transition from prior studies into the planned Phase 2b/3 CSU program [#SEC-8K-2026-03-30].
- • The same company-source record makes clear that study start timing depends on additional funding, so financing risk can override clinical progress for equity holders at the current stage [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].
Catalyst clock
2026-09-30
Financing is still the gating variable for the next CSU study step
Lead driver: Sentiment · See AI snapshot
Momentum
61
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
31
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 61.3 / Value 41.2 / Sentiment 31.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-07-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-07-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$28.02M
Beta
3.09
Shares Out
28.08M
P/E (TTM) · Derived
-0.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.39
Rev YoY
-
EPS YoY
-94.5%
Gross Margin
-
Op Margin
-
Net Debt
-$27.46M
Current Ratio
1.48
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data